- Why Agriculture Needs Gene Editing Now
- CRISPR vs Traditional GMO: A Critical Distinction
- CRISPR Crops: Disease Resistance
- CRISPR Crops: Yield, Nutrition & Climate
- CRISPR Livestock: Cattle, Pigs & Poultry
- CRISPR Fish & Aquaculture
- Gene Drives: Rewriting Wild Populations
- Xenotransplantation: Pig Organs for Humans
- The Regulatory Landscape: US vs EU vs Rest
- The Story: The Gardener and the Wild Forest
Section 1 — Why Agriculture Needs Gene Editing Right Now
The food security numbers are stark. The world population will reach approximately 10 billion by 2050. Feeding 10 billion people on a warming planet — where droughts are more frequent, pathogens are more virulent, and arable land is being lost to sea level rise and desertification — will require either a radical expansion of farmland (environmentally catastrophic) or a dramatic increase in yield and resilience of existing crops.
Plant diseases alone already destroy an estimated 20–40% of the global food supply annually. A single fungal disease, wheat blast (Magnaporthe oryzae Triticum pathotype), threatens wheat harvests across South Asia and South America. Citrus greening disease (caused by the bacterium Candidatus Liberibacter asiaticus) has devastated the Florida orange industry, reducing production by more than 90% in 15 years. Bananas face existential threat from a new strain of Panama disease (Fusarium wilt TR4) that is spreading globally.
Climate change compounds these threats: higher temperatures and altered rainfall patterns are shifting the geographic ranges of pests and pathogens, bringing diseases to crops that have never evolved resistance. Traditional plant breeding — which requires crossing plants over many generations to introduce new traits — takes 10–20 years per crop improvement cycle. CRISPR can introduce a targeted genetic change in months. For a planet on a climate deadline, that difference in timescale is not incremental — it is existential.
Section 2 — CRISPR vs Traditional GMO: A Critical Legal and Scientific Distinction
The regulatory and public perception of CRISPR-edited crops hinges on a distinction that is scientifically meaningful but legally contentious: the difference between transgenesis (inserting genes from another species, the basis of traditional GMOs) and cisgenic editing (modifying genes already present in the crop species, which is what most CRISPR applications do).
A traditional transgenic GMO like Bt cotton contains a gene from Bacillus thuringiensis bacteria that was never in any cotton plant before. This is genuinely novel to the species. A CRISPR-edited wheat variety with a knocked-out susceptibility gene to blast fungus contains only sequences that exist in wheat — and the specific change (disrupting a gene) could theoretically arise through natural mutation. The scientific question is: is there a meaningful biological difference between a change that CRISPR made in a laboratory and the same change that could have arisen naturally?
Most regulatory scientists say no — the end product is the same, regardless of how it was made. But regulatory frameworks are not purely scientific; they are also political, and the political history of GMO opposition has profoundly shaped how CRISPR-edited crops are regulated globally.
Section 3 — CRISPR Crops: Disease Resistance
Wheat Blast Resistance
Wheat blast is a fungal disease caused by Magnaporthe oryzae Triticum pathotype that can destroy 100% of a wheat crop within days. It emerged in Brazil in 1985, spread across South America, and jumped to Bangladesh in 2016 — the first time it reached Asia, threatening the wheat supplies of India, Bangladesh, and neighbouring countries. No commercial wheat variety had resistance.
Researchers identified the reason for susceptibility: wheat contains three copies of a gene called TaMlo that encodes a protein the fungus exploits to gain entry to cells. Barley with natural mutations in the homologous Mlo gene is resistant to powdery mildew — a related fungal disease. The CRISPR strategy: use multiplexed guide RNAs to knock out all three copies of TaMlo simultaneously in wheat. The resulting plants showed dramatically reduced susceptibility to wheat blast in greenhouse and field trials. Because no foreign DNA was introduced — only native genes were disrupted — the USDA determined this wheat does not require GMO regulation. It could potentially be deployed in Bangladesh within years rather than the decades required for conventional breeding.
Citrus Greening Resistance
Citrus greening (Huanglongbing, HLB) is caused by a bacterium transmitted by the Asian citrus psyllid insect. It infects the phloem (nutrient transport tissue) of citrus trees, causing progressive decline, fruit drop, and death within 5–10 years. There is currently no cure. Florida’s orange juice industry, once producing 240 million boxes annually, now produces fewer than 20 million as infected groves are cleared.
Multiple CRISPR approaches are in development. One strategy targets the CsLOB1 gene in citrus, which the HLB bacterium activates to promote its own growth. Disrupting CsLOB1 promoter elements reduces bacterial colonisation and symptom development. A second strategy uses CRISPR to enhance expression of antimicrobial peptides in phloem cells. These are in greenhouse trials; field trials in Florida began in 2024 under USDA regulatory oversight.
Powdery Mildew Resistance in Multiple Crops
Powdery mildew fungi (Blumeria, Erysiphe, Sphaerotheca) infect hundreds of crop species including wheat, barley, tomato, cucumber, and grapes. The Mlo gene family (the same family targeted for wheat blast resistance) is exploited by powdery mildew in many crops. CRISPR knockout of Mlo homologues has demonstrated broad-spectrum powdery mildew resistance in tomato, cucumber, and grapevine without apparent fitness costs. Several CRISPR-edited tomato and cucumber varieties with powdery mildew resistance have been approved or are in regulatory review in the US and Japan.
Section 4 — CRISPR Crops: Yield, Nutrition & Climate Adaptation
High-Oleic Canola and Soybeans
Canola oil high in oleic acid is more heat-stable (better for frying), has a longer shelf life, and has a healthier fatty acid profile than standard canola. Traditional breeding produced high-oleic canola but with yield penalties. CRISPR editing of the fatty acid desaturase genes (FAD2 and FAD3) in canola precisely disrupts the enzymes that convert oleic acid to linoleic and linolenic acid, producing oils with >80% oleic content without the yield penalty. The Cibus CRISPR canola variety received USDA non-regulated status in 2019 and is now grown commercially in Canada and the US.
Non-Browning Mushrooms and Arctic Apple
A CRISPR-edited white button mushroom developed at Penn State was the first CRISPR-edited food product to receive US regulatory clearance, in 2016, under the Obama administration. The edit disrupted genes encoding polyphenol oxidase enzymes that cause browning — the same mechanism that turns apple flesh brown when cut. The non-browning mushrooms reduce food waste significantly. Similarly, Arctic Apples (non-browning, though developed by RNA silencing rather than CRISPR) set the precedent for the commercial pathway that CRISPR produce is now following.
Drought Tolerance and Climate Adaptation
CRISPR is being applied to improve crops for water-limited environments. Researchers have edited the stomatal response genes in wheat and maize to reduce water loss under drought conditions. In rice, CRISPR knockout of the OsERA1 gene improves drought tolerance without yield penalty. Sorghum with edited Stay-Green genes maintains photosynthetic capacity longer under drought. These traits are critical for food security in sub-Saharan Africa and South Asia, where rainfall variability is increasing. Several drought-tolerant varieties are in advanced field trials.
Nutritional Enhancement: High-Amylose Wheat and Reduced Acrylamide
CRISPR has been used to increase resistant starch content in wheat by disrupting starch branching enzyme genes, producing flour with lower glycaemic index. In potatoes, disruption of the asparagine synthetase gene (StAsp1) and vacuolar invertase gene reduces acrylamide formation during high-temperature cooking (frying, baking) — a potential carcinogen formed from asparagine + reducing sugars. The Simplot Innate potato (using RNA silencing, not CRISPR) proved the commercial path; CRISPR versions are in development.
Section 5 — CRISPR Livestock: Cattle, Pigs & Poultry
Hornless Cattle: Welfare Without Invasive Surgery
Dehorning — physically removing horns from cattle to prevent injury to other animals and farm workers — is one of the most common and painful procedures in livestock management, performed on hundreds of millions of cattle annually without anaesthesia. Natural hornlessness (the “polled” trait) exists in some beef breeds but not in dairy breeds like Holsteins, which have higher milk production. The polled trait is caused by a naturally occurring mutation in the POLLED locus on chromosome 1.
Recombinator/Acceligen (now part of Hendrix Genetics) used CRISPR to introduce the natural polled mutation into elite dairy bulls. The resulting gene-edited bulls are completely hornless, maintain full dairy genetics, and their offspring are also hornless. No foreign DNA is introduced — it is the same mutation that exists naturally in Hereford cattle, introduced into Holstein genetics. This is perhaps the clearest example of CRISPR delivering an animal welfare benefit with no downside. The cattle were in regulatory review with the FDA as of 2024; the FDA’s new framework for intentional genomic alterations in animals covers these applications.
PRRS-Resistant Pigs
Porcine Reproductive and Respiratory Syndrome (PRRS) is the most economically damaging disease in the global swine industry, costing US pork producers alone an estimated $664 million annually. The PRRS virus infects pigs via CD163, a receptor on macrophages. Researchers at Edinburgh’s Roslin Institute (the same institute that cloned Dolly the sheep) used CRISPR to delete a small domain of the CD163 gene that the virus uses for cell entry. PRRS-resistant pigs that are otherwise completely normal — healthy, growing normally, with normal immune function against other pathogens — have been produced and validated. US regulatory approval would allow these animals to enter the commercial supply chain.
African Swine Fever Resistance
African Swine Fever (ASF) is a devastating viral disease with near-100% mortality in infected pigs and no vaccine or treatment. It has swept through Asian pig populations since 2018, causing the deaths of hundreds of millions of pigs and dramatically increasing global pork prices. Some warthogs in sub-Saharan Africa carry a natural resistance allele in a gene called RELA that limits the inflammatory response to ASF virus. CRISPR researchers have introduced this warthog resistance allele into domestic pigs, with encouraging early results showing reduced susceptibility to ASF infection.
Influenza-Resistant Chickens
Avian influenza has caused the culling of hundreds of millions of chickens globally. Researchers at the Roslin Institute identified that the influenza virus hijacks a host protein called ANP32A to replicate. CRISPR knockout of ANP32A in chickens produced birds that were highly resistant to H9N2 influenza in lab challenge experiments. While full resistance was not achieved (the virus could adapt by using related ANP32 family members), the approach demonstrates the feasibility of engineering innate viral resistance into livestock.
Section 6 — CRISPR Fish & Aquaculture
Aquaculture supplies more than 50% of the fish consumed globally and is the fastest-growing food production sector. CRISPR is being applied to improve productivity, reduce environmental impact, and enhance nutritional quality of farmed fish.
Faster-Growing Tilapia and Salmon
Growth hormone regulation in fish is controlled partly by myostatin, a protein that limits muscle growth. CRISPR knockout of the myostatin gene in tilapia and carp produces fish with dramatically increased muscle mass and faster growth — a trait also seen in naturally occurring myostatin mutants (“double-muscled” cattle and some whippet dogs). The CRISPR-edited tilapia require less feed per unit of weight gain, reducing the environmental footprint of production. In laboratory settings, double-muscled tilapia have been produced with 20–30% higher body weight at the same age.
Sterile Salmon for Containment
A major environmental concern with farmed salmon escapees is genetic introgression into wild salmon populations. CRISPR can produce reproductively sterile salmon by disrupting genes required for gonadal development. These sterile fish cannot reproduce even if they escape to rivers, eliminating the risk of genetic contamination of wild populations. Several companies are developing sterile CRISPR salmon as a containment strategy that is more reliable than physical barriers alone.
Omega-3 Enhanced Fish and Oilseed Crops
The long-chain omega-3 fatty acids EPA and DHA, found in fish oil, are important for human cardiovascular and neurological health. Farmed fish obtain these from wild-caught fish used in their feed — an unsustainable practice that depletes wild fish stocks. CRISPR has been used to engineer the fatty acid synthesis pathway in camelina (an oilseed crop) to produce EPA and DHA at levels comparable to fish oil. Camelina oil-fed salmon accumulate omega-3s without requiring any wild fish in their diet. This CRISPR-modified camelina received USDA non-regulated status in 2019.
Section 7 — Gene Drives: The Most Powerful and Controversial CRISPR Application
A gene drive is a genetic system that spreads a CRISPR edit through an entire wild population far faster than standard inheritance allows. In normal inheritance, a heterozygous individual (one edited copy, one wild-type copy) passes the edit to only 50% of offspring. A gene drive converts the wild-type copy to the edited version in every individual that inherits it, so nearly 100% of offspring carry the edit. A drive allele can spread through an entire species within 10–20 generations.
Malaria Mosquito Gene Drives: The Most Advanced Application
Malaria kills approximately 600,000 people annually, mostly children under five in sub-Saharan Africa. The primary vector is Anopheles gambiae mosquitoes. Two gene drive strategies are being developed:
Targets the doublesex gene, which controls sex determination. Drive allele disrupts doublesex in females, causing them to develop intersex morphology and be sterile. Males are unaffected and spread the drive. After several generations, the proportion of fertile females drops dramatically and the population collapses. In cage experiments, Target Malaria’s suppression drive reduced caged Anopheles gambiae populations to zero within 7–11 generations.
Instead of eliminating the mosquito population, spreads a gene that prevents the mosquito from transmitting the malaria parasite. Targets genes required for Plasmodium development in the mosquito gut. The mosquito population persists but cannot transmit malaria. Theoretically safer because the mosquito’s ecological role is preserved; practically harder to implement because genes that reduce malaria transmission may also reduce mosquito fitness, limiting drive spread.
The Ecological Risks of Gene Drives
Anopheles gambiae mosquitoes are not ecologically inert. They serve as pollinators for some plant species, as prey for bats, birds, and other insects, and as hosts for parasites other than malaria. Eliminating or dramatically suppressing them in sub-Saharan Africa could have cascading ecological effects that are difficult to predict. The fundamental challenge: once a gene drive is released into the wild, it is potentially irreversible.
The scientific community has proposed several containment approaches. Daisy chain drives use a series of interdependent drive elements, each of which requires the one below it to spread, but the lowest element spreads only by standard Mendelian inheritance. This localises the drive geographically. Immunising drives (or daisy quorum drives) are designed to spread to a local population and then stop. Reversal drives could potentially spread a second edit that restores the wild-type allele if the first drive causes unforeseen harm.
Section 8 — Xenotransplantation: CRISPR Pig Organs for Humans
The global shortage of donor organs kills tens of thousands of people annually who die waiting for a heart, kidney, or liver transplant. Pigs are anatomically similar to humans in organ size and physiology, and have been proposed as xenotransplant donors for decades — but three barriers prevented this: (1) pig cells express surface antigens recognised as foreign by the human immune system, causing hyperacute rejection; (2) pig retroviruses (PERVs) could potentially infect human cells; (3) porcine organs have different physiological parameters (coagulation, complement regulation) than human organs.
CRISPR has addressed all three barriers simultaneously. In 2021, eGenesis (founded by Harvard CRISPR pioneer George Church) reported the creation of pigs with 69 CRISPR edits: three pig antigen genes knocked out, nine human regulatory genes knocked in, and all 25 copies of PERV in the pig genome inactivated. These genetically modified pigs are the most extensively CRISPR-edited animals ever created.
In March 2024, surgeons at Massachusetts General Hospital performed the first transplant of a genetically modified pig kidney into a living human patient. The recipient, Richard Slayman, a 62-year-old with end-stage renal disease, received the kidney from a 10-gene-edited pig. The transplanted kidney began functioning immediately and Slayman was discharged within two weeks. He died two months later from causes unrelated to the transplant, but the transplanted kidney was still functioning at the time of his death. In 2024, a second xenotransplant recipient (a woman with a pig kidney) had the kidney functioning for several months. These are extraordinary preliminary results that open a new era in organ transplantation.
Section 9 — The Regulatory Landscape: US, EU, and the Rest of the World
How CRISPR-edited crops and animals are regulated varies enormously across jurisdictions and has profound implications for where these technologies are developed, grown, and consumed. The divergence between the US and EU is particularly stark and reflects deeper philosophical differences about the relationship between technology, risk, and precaution.
The USDA’s 2020 SECURE rule exempts most CRISPR-edited crops from GMO regulation if the edit could have arisen through conventional breeding and no plant pest sequences are introduced. This means most CRISPR knockouts and small edits do not require federal review before commercialisation. The FDA has separate authority over animals with “intentional genomic alterations” and is developing a framework for CRISPR livestock and fish. This pragmatic, product-focused approach has made the US the leading country for CRISPR crop development.
A 2018 European Court of Justice ruling determined that all gene-edited organisms fall under the EU’s strict GMO Directive, requiring lengthy risk assessments, traceability, and labelling requirements that have effectively blocked CRISPR crop development in Europe. However, in 2023 the European Commission proposed new rules that would create a separate regulatory category for “new genomic techniques” (NGTs) including CRISPR, potentially allowing simpler approval for edits that could have arisen through natural variation. EU Parliament passed the NGT regulation in 2024; implementation will take several years.
Japan, Australia, Brazil, Argentina, and Canada have all adopted relatively permissive frameworks for CRISPR-edited crops, exempting small edits from full GMO regulation. Japan approved the first CRISPR food product (high-GABA tomato for blood pressure) for commercial sale in 2021. Brazil has exempted CRISPR crops without foreign DNA from GMO rules since 2018. China has approved CRISPR editing in a biosafety certificate system. India, Africa, and most developing nations are still formulating frameworks, creating both opportunity (for agricultural innovation) and risk (of regulatory gaps).
The Gardener, the Farmer, and the Forest at the Edge of the World
There is a gardener who has tended the same wheat field for five thousand years. Her ancestors selected the tallest plants, the fullest heads of grain, the most vigorous seedlings, crossing them season after season to slowly shape a crop that could feed a village. The work was patient and generational. Then a fungus arrived on the wind from across the ocean, and within days the entire field was ash-grey, the heads of wheat collapsed and empty. Five thousand years of work, gone in a week. This is wheat blast. It is real, it is spreading, and traditional breeding cannot keep pace.
CRISPR gives the gardener a new tool. Instead of waiting twenty years to breed resistance into the crop — a process of crossing and back-crossing and selection that takes a human lifetime — she can reach inside the wheat genome and close the door the fungus uses to enter. The wheat is still her wheat. The genome is still the wheat’s own genome. She has not imported a door from another species; she has simply locked one that was already there. The wheat grows. The fungus cannot enter. The field survives.
Across the fence, a farmer tends a herd of Holstein dairy cows. Every spring, he spends a week doing one of the most painful jobs in agriculture: dehorning calves, removing horn buds with hot irons or caustic paste, without anaesthesia, because the regulations do not require it and the economics do not allow it. He has done this his entire life. He does not like it. Now he has the option of ordering bulls whose genomes carry the natural polled mutation — a change that exists in Hereford cattle, simply moved into his Holsteins by CRISPR. No foreign DNA. No unknown risks. Just hornless calves that never need dehorning. He is not creating a monster. He is eliminating a monthly ritual of unnecessary pain.
Further out, at the edge of the world, is a forest. In the forest lives the Anopheles mosquito. It feeds on people sleeping in their huts. It carries a parasite. Every year, 600,000 people — most of them children under five — die from the disease it carries: malaria. Scientists have developed a gene drive that could spread through this mosquito population and prevent it from transmitting the parasite. In cage experiments, it worked. The mosquitoes died out. No more malaria transmission, in a cage. The question now is not whether it works. The question is whether to open the cage.
The gardener and the farmer are making changes at the edge of a farm. If something goes wrong, it stays local. The mosquito gene drive crosses a different threshold: it would change the ecology of an entire continent, potentially permanently. The drive cannot be recalled once it spreads. This is not a reason not to do it — 600,000 deaths a year is not an argument for caution, it is an argument for urgency. But it is a reason to do it carefully, with full ecological assessment, community consent, and reversibility mechanisms. The forest is not a farm. The rules are different.
And then there is the pig. In a surgical suite in Boston, a surgeon holds in her hands a kidney. It came from a pig. A pig with 69 CRISPR edits, meticulously removing the molecular flags that would cause the human immune system to attack it, inserting the human proteins that would help it integrate, silencing the dormant viruses that might wake up and cause harm. The kidney goes in. It works. A man who would have died on a dialysis machine walks out of the hospital.
The gardener, the farmer, the scientist in the forest, and the surgeon in Boston are all using the same tool. But the scale of their ambition — and the scale of their responsibility — grows enormously from one to the next. That progression, from locked door in a wheat genome to a gene drive for an entire continent, is not just a story about technology. It is a story about the expanding reach of human intention, and the expanding weight of human consequence. CRISPR did not create this tension. It simply made it undeniable.
References & Further Reading
- Wang et al. (2014) — Simultaneous editing of three homoeoalleles in hexaploid bread wheat confers heritable resistance to powdery mildew. Nature Biotechnology 32:947. — First demonstration of multiplexed CRISPR editing in polyploid wheat.
- Komor et al. (2018) — CRISPR-edited crops: regulatory status and potential in food security. Nature Plants. — Comprehensive review of crop applications.
- Kyrou et al. (2018) — A CRISPR-Cas9 gene drive targeting doublesex causes complete population suppression in caged Anopheles gambiae mosquitoes. Nature Biotechnology 36:1062. — The landmark gene drive suppression paper.
- Niu et al. (2017) — Inactivation of porcine endogenous retrovirus in pigs using CRISPR-Cas9. Science 357:1303. — George Church lab PERV inactivation in pigs.
- USDA SECURE Rule (2020) — APHIS SECURE Rule — The US regulatory framework for CRISPR crops.
- Esvelt & Gemmell (2017) — Conservation demands safe gene drive. PLOS Biology. — The definitive case for ecological caution with gene drives.
- Massachusetts General Hospital (2024) — First pig-to-human kidney xenotransplant in a living recipient. massgeneral.org/news
- Agriculture needs CRISPR urgently. 40% of global food supply is lost to disease and pests. Population grows to 10 billion by 2050. Climate change spreads pathogens faster. Traditional breeding takes 20 years; CRISPR takes months.
- CRISPR knockouts are scientifically distinct from transgenic GMOs. No foreign DNA, targeted edit, potentially indistinguishable from natural mutation. US USDA exempts most CRISPR knockouts from GMO regulation. EU is moving toward a similar framework.
- Disease resistance is the most advanced crop application. TaMlo knockout wheat (blast resistance), CsLOB1 citrus (greening resistance), Mlo-edited tomato/cucumber (powdery mildew). Some already in commercial development or field trials.
- Livestock applications address welfare and disease. Hornless dairy cattle (dehorning elimination), PRRS-resistant pigs (economic disease), ASF-resistant pigs (potential epidemic control), influenza-resistant chickens. FDA framework for IGA animals is in development.
- Gene drives can spread through wild populations within 20 generations. Doublesex suppression drive eliminated Anopheles gambiae in cage experiments. No wild release yet. Ecological risk assessment and community consent are prerequisites. Containment drives (daisy chain, reversal) are in development.
- Xenotransplantation is becoming real. 69-gene-edited pig kidneys transplanted into living humans in 2024 with initial function. eGenesis and others in FDA compassionate use pathway. Pig organ transplants could address the donor organ shortage within this decade.
- Regulatory divergence is the biggest barrier. US (permissive for knockouts), EU (restrictive but changing), Japan/Brazil/Argentina (permissive). Access to CRISPR crops for developing world farmers depends on regulatory frameworks that do not yet exist in most of the countries with the highest food security need.